Dyax will use its antibody libraries to screen for clinical candidates, and the CSIRO will contribute assays, reagents, and preclinical work.



Dyax and the Division of Molecular and Health Technologies of the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia’s national scientific research agency, entered into a collaboration for the discovery and development of therapeutic antibodies to treat cancer.


During the discovery phase of the collaboration, Dyax will use its antibody libraries to screen for clinical candidates, and CSIRO will provide reagents and in vitro assays as well as certain in vivo and preclinical development work. Upon successful completion of the discovery work, CSIRO and Dyax will have the option to advance the antibody lead(s) into clinical development under the terms of a global codevelopment and commercialization agreement.


“We are pleased to have entered into this collaboration with CSIRO, and are confident that Dyax’s antibody libraries will again produce quality clinical leads that may provide a novel approach to treating cancer,” remarks Henry E. Blair, chairman and CEO of Dyax.








This site uses Akismet to reduce spam. Learn how your comment data is processed.